JP2013526705A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013526705A5 JP2013526705A5 JP2013510115A JP2013510115A JP2013526705A5 JP 2013526705 A5 JP2013526705 A5 JP 2013526705A5 JP 2013510115 A JP2013510115 A JP 2013510115A JP 2013510115 A JP2013510115 A JP 2013510115A JP 2013526705 A5 JP2013526705 A5 JP 2013526705A5
- Authority
- JP
- Japan
- Prior art keywords
- stem cell
- determining
- stem cells
- neurodegenerative disease
- contacting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 45
- 230000004770 neurodegeneration Effects 0.000 claims description 21
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 21
- 230000011987 methylation Effects 0.000 claims description 14
- 238000007069 methylation reaction Methods 0.000 claims description 14
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 claims description 10
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims description 10
- 101150008375 Pou4f1 gene Proteins 0.000 claims description 10
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims description 10
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims description 10
- -1 TuJ1 Proteins 0.000 claims description 9
- 239000002771 cell marker Substances 0.000 claims description 9
- 230000004069 differentiation Effects 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 9
- 108010033040 Histones Proteins 0.000 claims description 8
- 102000006947 Histones Human genes 0.000 claims description 8
- 229930003270 Vitamin B Natural products 0.000 claims description 6
- 239000002207 metabolite Substances 0.000 claims description 6
- 235000019156 vitamin B Nutrition 0.000 claims description 6
- 239000011720 vitamin B Substances 0.000 claims description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 4
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 4
- 102000004889 Interleukin-6 Human genes 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 4
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 229940064128 l-methylfolate Drugs 0.000 claims description 3
- 235000007635 levomefolic acid Nutrition 0.000 claims description 3
- 239000011578 levomefolic acid Substances 0.000 claims description 3
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical group C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 claims description 3
- 229940100601 interleukin-6 Drugs 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39532110P | 2010-05-11 | 2010-05-11 | |
| US61/395,321 | 2010-05-11 | ||
| PCT/US2011/033387 WO2011142952A1 (en) | 2010-05-11 | 2011-04-21 | Method of detecting and profiling progression of the risk of neurodegenerative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013526705A JP2013526705A (ja) | 2013-06-24 |
| JP2013526705A5 true JP2013526705A5 (https=) | 2014-03-27 |
Family
ID=44914644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013510115A Pending JP2013526705A (ja) | 2010-05-11 | 2011-04-21 | 神経変性疾患のリスクの推移を検出およびプロファイリングする方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20130029998A1 (https=) |
| EP (1) | EP2569625A4 (https=) |
| JP (1) | JP2013526705A (https=) |
| CA (1) | CA2795438A1 (https=) |
| WO (1) | WO2011142952A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108289937A (zh) | 2015-06-03 | 2018-07-17 | 爱兰细胞技术公司 | 用于产生和递送来自干细胞的有益因子的方法和装置 |
| US10282875B2 (en) | 2015-12-11 | 2019-05-07 | International Business Machines Corporation | Graph-based analysis for bio-signal event sensing |
| CN109415431A (zh) * | 2016-04-20 | 2019-03-01 | 爱兰细胞技术公司 | 与k180二甲基化h1.0蛋白相关的组合物和方法 |
| CN110506057B (zh) | 2017-02-17 | 2023-09-29 | 百时美施贵宝公司 | Alpha突触核蛋白抗体及其应用 |
| JP7252953B2 (ja) | 2017-10-25 | 2023-04-05 | エアラン セル テクノロジーズ， インコーポレイテッド | Ｈ１．０ｋ１８０ｍｅ２抗体、その作製および使用の方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7025A (en) * | 1850-01-15 | Buckle | ||
| US11016A (en) * | 1854-06-06 | Method of turning hubs | ||
| US20050037992A1 (en) * | 2003-07-22 | 2005-02-17 | John Lyons | Composition and method for treating neurological disorders |
| CN101909630A (zh) * | 2007-11-02 | 2010-12-08 | 新加坡科技研究局 | 预防和治疗肿瘤的方法和化合物 |
| JP4873510B2 (ja) * | 2008-07-01 | 2012-02-08 | 学校法人日本大学 | 標的遺伝子特異的ヒストン修飾制御剤 |
-
2011
- 2011-04-21 EP EP11780997.0A patent/EP2569625A4/en not_active Withdrawn
- 2011-04-21 WO PCT/US2011/033387 patent/WO2011142952A1/en not_active Ceased
- 2011-04-21 JP JP2013510115A patent/JP2013526705A/ja active Pending
- 2011-04-21 CA CA2795438A patent/CA2795438A1/en not_active Abandoned
- 2011-04-21 US US13/640,545 patent/US20130029998A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013526705A5 (https=) | ||
| Huang et al. | The role of the antioxidant response in mitochondrial dysfunction in degenerative diseases: Cross‐talk between antioxidant defense, autophagy, and apoptosis | |
| Deng et al. | Autophagy receptors and neurodegenerative diseases | |
| Villemagne et al. | In vivo tau imaging: obstacles and progress | |
| Walton | Aluminum disruption of calcium homeostasis and signal transduction resembles change that occurs in aging and Alzheimer's disease | |
| Ghosh et al. | Calcium/calmodulin-dependent kinase II and Alzheimer’s disease | |
| Liu et al. | Lipid metabolism in Alzheimer’s disease | |
| Musunuri et al. | Quantification of the brain proteome in Alzheimer’s disease using multiplexed mass spectrometry | |
| Amadio et al. | nELAV proteins alteration in Alzheimer's disease brain: a novel putative target for amyloid-β reverberating on AβPP processing | |
| H Peden et al. | Molecular pathology in neurodegenerative diseases | |
| Coskuner et al. | Adenosine triphosphate (ATP) reduces amyloid-β protein misfolding in vitro | |
| HRP20230186T1 (hr) | METODA PROCJENE RIZIKA OD PML-a | |
| JP2013250478A5 (https=) | ||
| HRP20140937T1 (hr) | POSTUPAK ZA OTKRIVANJE AĂź-SPECIFIÄŚNIH PROTUTIJELA U BIOLOŠKOM UZORKU | |
| JP2011121949A5 (https=) | ||
| Shen et al. | Proteomic profiling of cerebrum mitochondria, myelin sheath, and synaptosome revealed mitochondrial damage and synaptic impairments in association with 3× Tg‐AD mice model | |
| WO2009100953A3 (en) | Diagnostic method | |
| Liu et al. | Effects of lead exposure on the expression of amyloid β and phosphorylated tau proteins in the C57BL/6 mouse hippocampus at different life stages | |
| BR112014009223A8 (pt) | método para o diagnóstico da doença de niemann-pick | |
| Zhao et al. | Impaired lysosomal cobalamin transport in Alzheimer's disease | |
| Vishnu | Can tauopathy shake the amyloid cascade hypothesis? | |
| EP4289970A3 (en) | Circulating serum microrna biomarkers and methods for alzheimer's disease diagnosis | |
| CN208966931U (zh) | 一种装有磨损指示器的气鼓式制动器 | |
| EP2762494A3 (en) | Monoclonal antibodies against scrapie prion protein (PrPSc), and the use thereof | |
| Meiliana et al. | New insight in the molecular mechanisms of neurodegenerative disease |